TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8302922

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at 0.1 microgram.kg‐1.min‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trimethaphan (TMP) at 10 micrograms.kg‐1.min‐1
Number of subjects: 30
Study: 3539826

Group type: EXPERIMENTAL
Intervention: Oral timolol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 132
Study: 28730396

Group type: EXPERIMENTAL
Intervention: FRIENDS for Life intervention administered by trained teachers
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: FRIENDS for Life intervention for children with elevated depressive symptoms at baseline
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: FRIENDS for Life intervention with teachers attending more supervision sessions
Number of subjects: 695

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 695
Study: 26360125

Group type: EXPERIMENTAL
Intervention: Once-daily extended-release tacrolimus
Number of subjects: 91

Group type: COMPARATOR
Intervention: Twice-daily tacrolimus
Number of subjects: 91
Study: 24678064

Group type: EXPERIMENTAL
Intervention: Topical cocaine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Topical adrenaline
Number of subjects: 37
Study: 21308791

Group type: EXPERIMENTAL
Intervention: Atorvastatin and ezetimibe on top of oral anticoagulation therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 20519663

Group type: COMPARATOR
Intervention: Control arm with standard advice (IDPP-1)
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Metformin (n = 125, IDPP-1)
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: LSM + Metformin (n = 121, IDPP-1)
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: LSM + Pioglitazone (n = 298, IDPP-2)
Number of subjects: 845
Study: 18509244

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 administration for 6 months
Number of subjects: 36
Study: 11169027

Group type: COMPARATOR
Intervention: Cuprophan hemodialysis (HD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Peritoneal dialysis (PD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-flux polysulfon (F6 HPS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-flux polysulfon (F60S)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study: 9987422

Group type: EXPERIMENTAL
Intervention: Breastfeeding campaign (panel presentation and video)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group (no exposure to the campaign)
Number of subjects: 412
Study: 7841431

Group type: EXPERIMENTAL
Intervention: AUDIT
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CAGE
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CAGE (Male African group)
Number of subjects: 122
Study: 3168077

Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon treatment (5 IU three times weekly by subcutaneous injection for 16 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon treatment
Number of subjects: 20
Study: 29792234

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 134
Study: 29871264

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray combined with montelukast (MOM+M)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray combined with loratadine (MOM+L)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mometasone furoate aqueous nasal spray (MOM)
Number of subjects: 57
Study: 25052218

Group type: EXPERIMENTAL
Intervention: Jet injector
Number of subjects: 53

Group type: COMPARATOR
Intervention: Needle infiltration
Number of subjects: 53
Study: 23998952

Group type: EXPERIMENTAL
Intervention: ITAREPS
Number of subjects: 45
Study: 21466700

Group type: EXPERIMENTAL
Intervention: Operative treatment (simple end-to-end repair of the tendon with no augmentation)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Parallel patient preference group (non-operative management)
Number of subjects: 52
Study: 18050368

Group type: EXPERIMENTAL
Intervention: Etidronate disodium (200 mg per day for 2 weeks) with 3.0 g of calcium lactate and 0.75 microg of alphacalcidol daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group receiving only calcium lactate and alphacalcidol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Etidronate disodium
Number of subjects: 102
Study: 16412157

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 12519633

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10852452

Group type: EXPERIMENTAL
Intervention: Raloxifene (Evista, 60 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE; Premarin, 0.625 mg/day)
Number of subjects: 100
Study: 9337603

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR) followed by exposure (EXP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention followed by exposure (EXP)
Number of subjects: 60
Study: 8096389

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate patches releasing 15 mg/24 h
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30259284

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 153
Study: 29409556

Group type: EXPERIMENTAL
Intervention: Optimal Default (OD)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Free Array (FA)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Suboptimal Default (SD)
Number of subjects: 129
Study: 27386644

Group type: EXPERIMENTAL
Intervention: Zaozhu Yinchen Recipe (ZZYCR), one dose per day for 24 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Silibin Meglumine Tablets, 20 mg thrice per day for 24 weeks
Number of subjects: 120
Study: 25238831

Group type: EXPERIMENTAL
Intervention: Educational intervention (workshops on nutrition and physical activity)
Number of subjects: 126
Study: 23063038

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open-loop (OL) system
Number of subjects: 10
Study: 20013441

Group type: EXPERIMENTAL
Intervention: Mix A of food additives
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Mix B of food additives
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (preservative)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Overall intake of food additives
Number of subjects: 1035
Study: 18374003

Group type: EXPERIMENTAL
Intervention: FES cycling at 15 rpm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FES cycling at 30 rpm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FES cycling at 50 rpm
Number of subjects: 9

Group type: COMPARATOR
Intervention: FES cycling at 15, 30, and 50 rpm
Number of subjects: 9
Study: 17409936

Group type: EXPERIMENTAL
Intervention: GSTP1 105Val allele
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: GSTP1*B haplotype
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: GSTP1 polymorphisms
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: GSTP1 105Val allele and GSTP1*B allele
Number of subjects: 108
Study: 12821739

Group type: EXPERIMENTAL
Intervention: High-dose cooling therapy for 1 hour
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-dose cooling therapy for 1 hour
Number of subjects: 84

Group type: COMPARATOR
Intervention: Daily cooling garment use for 1 hour each day for a month
Number of subjects: 84

Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 84
Study: 10834668

Group type: EXPERIMENTAL
Intervention: Alfentanil at a target plasma concentration of 100 ng/mL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alfentanil at a target plasma concentration of 200 ng/mL
Number of subjects: 8

Group type: COMPARATOR
Intervention: None (control)
Number of subjects: 8
Study: 9002092

Group type: EXPERIMENTAL
Intervention: 1-day Acuvue disposable soft contact lenses (BC 9.0 mm, diameter 14.2 mm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 14-day Acuvue disposable soft contact lenses (BC 8.8 mm, diameter 14.0 mm)
Number of subjects: 25
Study: 1455324

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 3975735

Group type: EXPERIMENTAL
Intervention: Drainage via Penrose dam
Number of subjects: 161

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 161
Study: 31437195

Group type: EXPERIMENTAL
Intervention: Blood loss ≥500ml
Number of subjects: 2335

Group type: EXPERIMENTAL
Intervention: Blood loss ≥1000ml
Number of subjects: 2335

Group type: EXPERIMENTAL
Intervention: Blood loss 500-999 ml
Number of subjects: 2335
Study: 29017803

Group type: EXPERIMENTAL
Intervention: Automated mobile phone messaging
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (historical TJA patients)
Number of subjects: 34
Study: 27094106

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 998
Study: 24418950

Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 613

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 613
Study: 23153014

Group type: EXPERIMENTAL
Intervention: Remote care (telehealth and telecare)
Number of subjects: 3
Study: 19665936

Group type: EXPERIMENTAL
Intervention: TENS at 80 pps
Number of subjects: 32

Group type: COMPARATOR
Intervention: TENS at 3 pps
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of TENS at 80 pps vs 3 pps
Number of subjects: 32
Study: 18265584

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Milligan‐Morgan's method
Number of subjects: 77
Study: 15934285

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy and IFN‐gamma treatment (1000000 IU im qod)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Specific immunotherapy (control group)
Number of subjects: 60
Study: 12468782

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg/d for 2 to 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9785786

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Number of subjects: 40
Study: 7894881

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Antidepressant alone (placebo)
Number of subjects: 62
Study: 2692686

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefuroxime and Metronidazole
Number of subjects: 0
Study: 327623

Group type: EXPERIMENTAL
Intervention: Primary radiation therapy for stage I cases without randomization, followed or not by maintenance chemotherapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mantle field therapy for supradiaphragmatic stage II, followed if necessary by prophylactic infradiaphragmatic irradiation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total abdominal irradiation for infradiaphragmatic stage II, followed by supradiaphragmatic prophylaxis if needed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two regimens of maintenance chemotherapy for all stages II, randomized.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two regimens of induction chemotherapy for stages III and IV, followed by maintenance chemotherapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation of the icebergs for stage III cases.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total irradiation for stages III or IV for centers desiring it.
Number of subjects: 0
Study: 31553134

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 20 mg single dose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg single dose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg/d for 7 days (multiple doses)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg single dose under fasted and fed conditions
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL)
Number of subjects: 27
Study: 31696504

Group type: EXPERIMENTAL
Intervention: Probiotic group (42 patients, 10M/32F, mean age 32.23 ± 10.3 years) treated with ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for one week, supplemented with probiotic mix (1 sachet twice a day for 10 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (42 patients, 15M/27F, mean age 59.01 ± 11.3 years) received the same antibiotic treatment without the probiotic mix
Number of subjects: 84
Study: 28108368

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: SP plus piperaquine (SP/PQ)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Passive control arm
Number of subjects: 616
Study: 26415792

Group type: EXPERIMENTAL
Intervention: Minimum effective cuff inflating volume group (MC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care group (RC)
Number of subjects: 0
Study: 24235233

Group type: EXPERIMENTAL
Intervention: Plant-derived antimicrobials (PDA) - trans-cinnamaldehyde (TC), carvacrol (CR), eugenol (EUG) at concentrations of 0.0, 0.25, 0.5, or 0.75%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorine (200 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wash water control (antibacterial-free)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant-derived antimicrobials (PDA) - CR and EUG
Number of subjects: 0
Study: 21470834

Group type: EXPERIMENTAL
Intervention: Acute bowel toxicity
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Higher prescribed dose
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Pretreatment bladder symptoms
Number of subjects: 788
Study: 19498009

Group type: EXPERIMENTAL
Intervention: Nitrite-preserved red meat (PM)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fresh red meat (RM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vegetarian (VEG) diet
Number of subjects: 28
Study: 16686560

Group type: EXPERIMENTAL
Intervention: WIPP training program (8 weeks, 2 days per week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 14660997

Group type: EXPERIMENTAL
Intervention: Guideline summary, peer comparison performance feedback, and patient specific chart reminders
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: HMG CoA reductase inhibitors
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 700
Study: 11182431

Group type: EXPERIMENTAL
Intervention: Support group intervention (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study: 8989069

Group type: EXPERIMENTAL
Intervention: Fluconazole (3 mg/kg daily orally) and placebo (100 mg/kg/daily orally)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Itraconazole (3 mg/kg daily orally) and flucytosine (100 mg/kg daily orally)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (3 mg/kg daily orally) and placebo (100 mg/kg daily orally)
Number of subjects: 85
Study: 1453306

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen immediately presurgically
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo before surgery and 600 mg ibuprofen postsurgically
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo at both time periods
Number of subjects: 60
Study: 2981982

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin and vindesine (PVD)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cisplatin and VP‐16‐213 (PVP)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cisplatin with VP‐16‐213 and vindesine (PVPVD)
Number of subjects: 167
Study: 30698812

Group type: EXPERIMENTAL
Intervention: Whey protein (WHEY)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soy protein (SOY)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Leucine-enriched soy protein (SOY + LEU)
Number of subjects: 36
Study: 31726649

Group type: EXPERIMENTAL
Intervention: Lifestyle e-coaching application
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 28632983

Group type: EXPERIMENTAL
Intervention: Circle of Security® (COS) intervention
Number of subjects: 12
Study: 26688233

Group type: EXPERIMENTAL
Intervention: Fiix-prothrombin time (Fiix-PT) monitoring
Number of subjects: 1156

Group type: COMPARATOR
Intervention: PT-INR monitoring (Control)
Number of subjects: 1156
Study: 23926117

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (E/S) + Niacin (N) (10/20 mg/day + titrated to 2 g/day)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Niacin (N) (titrated to 2 g/day)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Ezetimibe/Simvastatin (E/S) (10/20 mg/day)
Number of subjects: 577
Study: 21874559

Group type: EXPERIMENTAL
Intervention: 20 mg bilastine
Number of subjects: 21

Group type: COMPARATOR
Intervention: 10 mg cetirizine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: bilastine 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: bilastine 20 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: cetirizine 10 mg
Number of subjects: 21
Study: 19903187

Group type: EXPERIMENTAL
Intervention: Multiple-dose LRPT 40 mg/day for 7 days coadministered with single-dose rosiglitazone 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single-dose rosiglitazone 4 mg
Number of subjects: 12
Study: 17257457

Group type: EXPERIMENTAL
Intervention: Topical diclofenac epolamine plaster (DHEP)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 258
Study: 12939586

Group type: EXPERIMENTAL
Intervention: Initial treatment (various methods including vasoactive drugs, endoscopic therapy, combined therapy, balloon tamponade)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 465

Group type: COMPARATOR
Intervention: Variceal bleeding
Number of subjects: 465

Group type: COMPARATOR
Intervention: Nonvariceal bleeding
Number of subjects: 465
Study: 11466698

Group type: EXPERIMENTAL
Intervention: BCNU (150 mg/m(2) on Day 3) plus IFN‐alpha (12 million U/m(2) on Days 1‐3, Weeks 1, 3, and 5) every 7 weeks for a maximum of 6 cycles
Number of subjects: 275

Group type: COMPARATOR
Intervention: BCNU alone (200 mg/m(2) on Day 1)
Number of subjects: 275
Study: 9391690

Group type: EXPERIMENTAL
Intervention: Prehospital-initiated thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-hospital thrombolysis
Number of subjects: 0
Study: 8425660

Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia (mean blood glucose 2.6 +/- 0.28 mM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Euglycemia (mean blood glucose 6.3 +/- 0.89 mM)
Number of subjects: 25
Study: 3299443

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Blood Pressure Monitoring (BPM)
Number of subjects: 137
Study: 28326881

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each) for six weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26804247

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 24937535

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 23275013

Group type: EXPERIMENTAL
Intervention: Lirukang Granule (LRKG) combined with psychological intervention
Number of subjects: 470

Group type: COMPARATOR
Intervention: Lirukang Granule (LRKG)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Psychological intervention
Number of subjects: 470

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 470
Study: 21860279

Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone caproate
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 18281176

Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Conventional Syringe
Number of subjects: 209
Study: 17070151

Group type: EXPERIMENTAL
Intervention: Intracoronary nitroprusside (NTP) 60 microg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12859302

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg i.v.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 80
Study: 10881824

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting operation with stabilization
Number of subjects: 58

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting operation with cardiopulmonary bypass
Number of subjects: 58
Study: 9085960

Group type: EXPERIMENTAL
Intervention: Morphine (0.75, 1.0, or 1.5 mg bolus dose size)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Meperidine (9, 12, or 18 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Morphine and Meperidine
Number of subjects: 102
Study: 8448101

Group type: EXPERIMENTAL
Intervention: Articaine 4% with 20 micrograms epinephrine (2 mL)
Number of subjects: 20
Study: 2891754

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg intravenous intra-operative dose)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190